XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Tables)
9 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of exercisable share purchase warrants outstanding
  Number of Shares  Weighted Average Exercise Price ($)
 Balance, September 30, 2019   350,000   4.19
 Granted   150,000   3.17
 Balance, June 30, 2020   500,000   3.88

Schedule of share purchase warrants outstanding
          
Number  Exercise Price  Expiry Date
 350,000   $4.19   June 30, 2021
 150,000   $3.17   May 6, 2024
 500,000         
Schedule of outstanding stock purchase options
  Number of Shares  Weighted Average Exercise Price ($)  Weighted Average Grant Date Fair Value ($)  Aggregate intrinsic value ($)
 Outstanding, September 30, 2019    8,462,933    3.58        4,115,032
 Granted    1,695,000    2.96    2.27 
 Forfeited    (68,332)   3.01      
 Exercised    (13,335)   3.15      
 Outstanding, June 30, 2020    10,076,266    3.48        17,818,714
 Exercisable, June 30, 2020    7,284,183    3.67        12,366,473

 

Schedule of general and administrative expenses and research and development expenses
                    
   Three months ended June 30,  Nine months ended June 30,
   2020  2019  2020  2019
General and administrative  $575,451   $579,636   $1,863,869   $2,586,223 
Research and development   675,678    654,568    2,352,437    2,608,120 
Total share based compensation  $1,251,129   $1,234,204   $4,216,306   $5,194,343 

Schedule of weighted average assumptions for fair value of each option award
           
   2020   2019 
Risk-free interest rate   1.57%   2.91%
Expected life of options (years)   5.53    5.59 
Annualized volatility   97.80%   105.96%
Dividend rate   0.00%   0.00%